Morgan Stanley Maintains Overweight on Ultragenyx Pharmaceutical, Raises Price Target to $74

Morgan Stanley analyst Jeffrey Hung maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Overweight and raises the price target from $67 to $74.